Search

Dr Christopher Charles Herbert

Clinical oncology

 

  • Fee assured
Overview

About me

Dr Chris Herbert qualified in medicine at Birmingham University in 2000. He trained in Clinical Oncology in Bristol and completed his oncology training as a clinical research fellow at the British Columbia Cancer Agency in Vancouver, Canada, where he specialised in stereotactic radiosurgery and the treatment of benign and malignant adult brain tumours. Appointed as consultant Clinical Oncologist in Bristol in 2011, he has an interest in technical radiotherapy, specialising in the treatment of adult brain tumours, including stereotactic radiosurgery, and malignant melanoma. He has published work on stereotactic radiosurgery and external beam radiotherapy in international, peer reviewed journals.

Areas of interest

Treatment of skin cancers including meanoma. Treatment brain tumours, including the treatment of brain metastases with gamma knife radiosurgery

Medical secretaries

About me
My qualifications & training
My private practice
Consultant's practices
Information for healthcare professionals

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

  • X6950

    Clinical supervision of the planning of stereotactic radiosurgery e.g. SRT/SBRT and Gamma Knife - (1-5)

    Bristol Royal Infirmary (1-5) Bristol Haematology and Oncology Centre (1-5)

  • X0004

    Clinical supervision and planning for delivery of chemotherapy cycle 1 - 28 days - (1-5)

  • X0007

    Clinical supervision of external beam radiotherapy, up to and including 15 fractions or part thereof - (1-5)

Edit details Print page

The information contained on Finder is submitted by consultants, therapists and healthcare services, and these third parties declare it to be correct and compliant with their relevant regulatory bodies' standards and codes of conduct. We're unable to guarantee the accuracy of all of the information provided.

You can find out more about the information on Finder and our website terms of use here.